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Introduction {#sec1}
============

Type I interferons (IFNs), including IFN-β, play a central role in MTb restriction and pathogenesis ([@bib51], [@bib61], [@bib66]). Our previous studies unexpectedly showed that the virus- and IFN-inducible interferon-stimulated gene (ISG) IFITM3 was induced by MTb in primary human monocyte-derived macrophages (MDM) and was critically involved in MTb growth inhibition in human monocytic and alveolar epithelial cell lines ([@bib74]). These findings led us to speculate that mycobacteria directly trigger cytosolic RNA sensors that lead to transcription of IFN-β and of IFITM3 and other ISGs typically involved in the antiviral/IFN axis, which might also inhibit intracellular MTb growth in human cells.

Activation of cytosolic DNA sensing pathways by MTb infection leading to type I IFN production was first described in 2012 ([@bib56]), followed by observations from several laboratories that the cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING)/TANK binding kinase 1 (TBK1)/IFN regulatory factor 3 (IRF3) pathway was important for MTb-dependent type I IFN production ([@bib21], [@bib27], [@bib91], [@bib92]). STING and cGAS were also shown to restrict MTb growth with the demonstration that bone-marrow-derived macrophages (BMDMs) from cGAS^−/−^ and STING^−/−^ mice had a higher burden of MTb relative to BMDM from wild-type mice ([@bib92]).

The RLR proteins retinoid acid-inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5) are key components of the host cytosolic RNA sensing pathway ([@bib22], [@bib93]). Although RIG-I and MDA5 each preferentially respond to distinct double-stranded RNA (dsRNA) ligands---short polyphosphorylated dsRNA (RIG-I) and long dsRNA (MDA5)---both signal through a common adaptor, the mitochondrial antiviral signaling (MAVS) protein, leading to expression of IFN-β and other type I IFNs ([@bib35], [@bib76], [@bib87]). The IFN-inducible, cytoplasmic dsRNA-activated kinase protein kinase R (PKR), which is an RNA-sensing protein outside of the RIG-I/MDA5/MAVS axis, is also triggered by viral infection and by natural or synthetic dsRNA ([@bib15], [@bib24], [@bib33], [@bib43], [@bib63]).

A role for cytosolic RNA sensing via the RLR pathway in response to bacterial infection has emerged from studies in murine cells. In murine macrophages RIG-I and MDA5 have been shown to recognize RNA released by *Legionella pneumophila* ([@bib60]) and *Listeria monocytogenes* ([@bib1]), and RIG-I has been shown to recognize *Helicobacter pylori* RNA in murine dendritic cells ([@bib73]). Furthermore, MTb infection of murine BMDM and J774 cells resulted in increased RIG-I and MDA5 mRNA levels ([@bib7]), and MTb RNA actively released into the host cytoplasm has been shown to interact with RIG-I ([@bib18]).

Here, we show that the RNA sensors RIG-I, MDA5, MAVS, and PKR broadly inhibit MTb growth in human cells. Furthermore, we show that MTb stimulates RLR and PKR functional activity. We also demonstrate that the oral FDA-approved thiazolide drug nitazoxanide (NTZ) ([@bib5], [@bib77]), which we have recently shown to amplify RNA sensing and interferon pathways in response to virus and double-stranded RNA (dsRNA) ([@bib46]), potentiates MTb-driven RLR activity and significantly inhibits intracellular MTb growth in primary human cells. This study presents the first evidence of the involvement of the RLR/MAVS and PKR pathways in cell-intrinsic control of intracellular MTb growth, demonstrates the broad role of cytosolic RNA sensing proteins in the type I IFN response to MTb in human cells, and suggests this pathway as a potential target for host-directed approaches to treat tuberculosis disease.

Results {#sec2}
=======

MTb Infection Induces Expression of RIG-I, MDA5, and PKR mRNA in Primary Human MDM and THP-1 Cells {#sec2.1}
--------------------------------------------------------------------------------------------------

IFITM3, RIG-I, MDA5, and PKR are IFN-stimulated genes (ISGs) ([@bib50], [@bib53], [@bib58]), whereas MAVS has not been reported to be IFN inducible ([@bib53]). To determine if, as is the case with IFN-inducible IFITM3 ([@bib74]), RIG-I, MDA5, PKR, and/or MAVS gene expression is induced by MTb in human cells, we infected primary human MDM for 3 or 24 h with MTb strain H37Rv. By 24 h post-MTb infection, RIG-I, MDA5, and PKR mRNA levels significantly increased (p \< 0.0001), whereas constitutive MAVS gene expression was not further elevated ([Figure 1](#fig1){ref-type="fig"}A, left). We also examined IFN-β gene expression after 3 and 24 h of MTb infection and found that it too was highly induced at 24 h (p=\<0.000.1), and minimally, but significantly, induced by MTb at 3 h post-infection (p = 0.01) ([Figure 1](#fig1){ref-type="fig"}A, left).Figure 1MTb Infection Induces Gene Expression of Cytosolic RNA Sensing Proteins, Which Inhibit MTb Growth(A) Gene expression in MDM (left) or THP-1 cells (right) that were mock-infected or infected with MTb (H37Rv) at ratio of 1:10 cell:bacilli for 3 or 24 h (MDM) or 24 h (THP-1). Relative mRNA expression of RIG-I, MDA5, MAVS, PKR, or IFN-β measured by RT-PCR is indicated on the histogram. Data were analyzed using the unpaired Student\'s t-test and are presented as mean ± SEM of three independent experiments. Please see [Figure S1](#mmc1){ref-type="supplementary-material"}A for RNA analysis of RIG-I, MDA5, MAVS, PKR, and IFITM3 after H37Rv extract stimulation of THP-1 cells.(B) Knockdown of RIG-I by shRNA, MDA5 or MAVS by Cas9/CRISPR, or PKR by dCas9/CRISPR in THP-1 cells as described in [Methods](#sec4){ref-type="sec"} impairs the cytosolic RNA sensing pathway while leaving the cytosolic DNA sensing pathway intact. IFN-β mRNA expression levels were measured in the differentiated THP-1 control cells or RIG-I, MDA5, MAVS, PKR, or STING knockdown cells. THP-1 cells were treated with 5\'ppp RNA, poly I:C, or herring sperm DNA as indicated for eight hours. For each THP-1 cell line with an RNA sensor disruption we paired a matched control THP-1 cell line. In the case of the MDA5, MAVS, or STING disrupted cells, which were created by Cas9/CRISPR, we employed a WT THP-1 cell line that was parental to the specific Cas9/CRISPR clone as described previously ([@bib55], [@bib65], [@bib79]). In the case of the RIG-I disrupted cells, we used an shRNA control THP-1 cell line generated at the same time, and in the case of the PKR disrupted cells, which were generated by dCas9, we used a dCas9 control cell line as described in [Methods](#sec4){ref-type="sec"}. Data were analyzed using the unpaired Student\'s t-test and are presented as mean ± SEM of three independent experiments. Please see [Figure S1](#mmc1){ref-type="supplementary-material"}B for Western blot analyses showing ablation of protein expression of RIG-I, MDA5, MAVS, and PKR in THP-1 cells where expression of these genes have been disrupted.(C) Quantitative IFC analysis of THP-1 cells infected with H37Rv-mCherry at 1:10 cell:bacilli for 24 h or 48 h, comparing THP-1 control cells with cells in which RIG-I, MDA5, MAVS, or PKR expression was ablated as described in [Methods](#sec4){ref-type="sec"}. Dot plot graphs show the pixel intensity of intracellular mCherry in the infected cells after ImageStream acquisition. Data were analyzed using the Mann-Whitney Test and are representative of three independent experiments, acquiring ∼5,000 cells per sample each time. Please see [Figure S2](#mmc1){ref-type="supplementary-material"} for increase of MTb growth in STING- or cGAS-deficient THP-1 cells, and, please refer to [Figure S3](#mmc1){ref-type="supplementary-material"} for representative images of sensor-deficient and control THP-1 cells after ImageStream acquisition.(D) CFU assays at 0, 2, and 4 days post-MTb infection (1:10 cell:bacilli) of control THP-1 cells relative to THP-1 cells in which RIG-I, MDA5, MAVS, or PKR expression was ablated as indicated. At Day 0, the range of counts were as follows: RIG-I vs. control: 72 x 10^3^ ± 22 vs. 92 x 10^3^ ± 1; MDA5 vs. control: 17 x 10^3^ ± 8 vs. 6 x 10^3^ ± 3; MAVS vs. control: 18.1 x 10^3^ ± 8 vs. 6.3 x 10^3^ ± 3; PKR vs. control: 13 x 10^3^ ± 1.1 vs. 9 x 10^3^ ± 1.9. Data were analyzed using the unpaired Student\'s t-test and are presented as mean ± SEM of two independent experiments in triplicate.

We have previously used human monocytic THP-1 cells to study MTb-induced human gene transcription and the role of host factors in restriction of MTb ([@bib9], [@bib75], [@bib74]), including IFITM3 ([@bib74]). In a pattern similar to MDM, after 24 h of H37Rv MTb infection of THP-1 cells, mRNA levels of RIG-I (p = 0.002), MDA5 (p = 0.0001), and PKR (p = 0.006) were significantly increased, whereas MAVS mRNA levels were not ([Figure 1](#fig1){ref-type="fig"}A, right). This is consistent with a recent study showing an increase in MDA5 and PKR mRNA levels in MTb-infected human MDM and THP-1 cells ([@bib103]). MTb infection of THP-1 cells also led to a significant increase in IFN-β mRNA levels after 24 h (\<0.0001) ([Figure 1](#fig1){ref-type="fig"}A, right) as found in MDM. Thus, MTb infection stimulates RIG-I, MDA5, and PKR gene expression in both primary human MDM and THP-1 cells.

To examine if this was a consequence of live MTb infection, we also tested the ability of killed mycobacterial extracts to induce RIG-I, MDA5, and PKR mRNA levels. Treatment of THP-1 cells with MTb H37Rv whole-cell lysates for 24 h significantly induced RIG-I, MDA5, and PKR mRNA levels with no increase in MAVS mRNA levels in a pattern very similar to live infection ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Furthermore, IFITM3 mRNA levels were also induced by the MTb lysates ([Figure S1](#mmc1){ref-type="supplementary-material"}A). This result is consistent with our previous study showing that IFITM1-3 gene expression was induced by engagement of the pattern recognition receptors (PRRs) toll-like receptor 2 (TLR2) and TLR4 ([@bib74]), which recognize MTb-derived molecules ([@bib31]).

Disruption of Specific Cytoplasmic RNA Sensor Proteins Promotes Increased Intracellular MTb Growth in Human Cells {#sec2.2}
-----------------------------------------------------------------------------------------------------------------

Having established that MTb infection induces gene expression of the RLR proteins and PKR, we next tested the effect of disrupting expression of RIG-I, MDA5, MAVS, or PKR ([Figure S1](#mmc1){ref-type="supplementary-material"}B) upon intracellular MTb growth compared with its respective control THP-1 cell line. However, first we performed a control experiment to establish the RNA and DNA sensor responsiveness of the cell lines where the RNA sensor proteins had been perturbed. We stimulated each knockdown and control cell line with short (19-bp) dsRNA (5\'ppp dsRNA) and long (∼1.5--8 kb) dsRNA (poly I:C) ligands and with herring sperm DNA, a ligand stimulating the DNA sensing pathway, and measured IFN-β mRNA induction. We note that RIG-I preferentially interacts with shorter dsRNAs compared with MDA5 and PKR, which preferentially respond to longer dsRNAs ([@bib35], [@bib48], [@bib76], [@bib87]).

In response to 5\'ppp dsRNA, the RIG-I-deficient cells displayed significantly decreased expression of IFN-β mRNA (p = 0.007) compared with control cells, which is consistent with RIG-I\'s preference for shorter dsRNAs ([@bib35], [@bib76], [@bib87]). By contrast, 5\'ppp dsRNA stimulation of the MDA5-and PKR-deficient THP-1 cells did not result in significantly decreased (p = 0.09 and p = 0.095, respectively) IFN-β levels compared with control cells ([Figure 1](#fig1){ref-type="fig"}B). These results are consistent with the preferential response of MDA5 and PKR to longer dsRNAs ([@bib35], [@bib76], [@bib87]). Consistent with this finding, in response to poly I:C, the MDA5- or PKR-deficient cells displayed significantly decreased IFN-β expression (p = 0.001 and p = 0.024, respectively) compared with their respective controls ([Figure 1](#fig1){ref-type="fig"}B). As expected, cells deficient in MAVS, through which both RIG-I and MDA5 signal, displayed a significant decrease in IFN-β mRNA levels in response to both 5\'ppp dsRNA (p = 0.01) and poly I:C (p = 0.003) compared with their control THP-1 cells ([Figure 1](#fig1){ref-type="fig"}B).

Because there is potential crosstalk between the cytoplasmic DNA and RNA sensing pathways ([@bib102]), to rule out an impact of disruption of the RNA sensors upon DNA sensing activities we stimulated the RIG-I-, MDA5-, MAVS-, and PKR-deficient cell lines with herring sperm DNA (hsDNA), which activates the cGAS/STING pathway ([@bib32]). All of the RNA sensor-deficient cell lines displayed IFN-β gene expression levels equivalent to those of control cells in response to hsDNA ([Figure 1](#fig1){ref-type="fig"}B). As a control, we also stimulated STING-deficient THP-1 cells ([Figure S1](#mmc1){ref-type="supplementary-material"}B), which as expected did not respond to hsDNA as did its control THP-1 cell line ([Figure 1](#fig1){ref-type="fig"}B). Taken together, these data show that our RNA sensor-deficient cell lines displayed functional phenotypes reflecting the lack of the specific sensor that was targeted, and their DNA sensing pathway was intact.

To determine the role of each specific sensor in the cell-intrinsic inhibition of intracellular MTb growth, we next infected the RIG-I, MDA5, MAVS, or PKR-deficient THP-1 cell lines with fluorescently labeled H37Rv-mCherry MTb ([@bib83]) at a cell to bacteria ratio of 1:10 and compared their ability to restrict MTb growth as compared to their respective control THP-1 cells. MTb growth was then evaluated after 24 or 48 h by quantitative imaging flow cytometry (IFC) ([Figure 1](#fig1){ref-type="fig"}C) utilizing the ImageStream platform ([@bib10], [@bib37], [@bib74]). IFC permits discernment of internalized MTb bacilli from extracellular bacilli within acquired images, and thus data are generated in a high-throughput fashion from image analysis of specific cellular parameters ([@bib37], [@bib74]). Intensity of intracellular fluorescence per cell can then be plotted as a graph of pixel intensity ([@bib10], [@bib29], [@bib37]).

As shown in [Figure 1](#fig1){ref-type="fig"}C, inhibition of each of the RNA sensors resulted in highly significant increased growth of H37Rv-mCherry as detected by IFC/ImageStream relative to its control cell line at 24 h (RIG-I: p \< 0.0001; MDA5: p \< 0.0001; MAVS: p = 0.002) or 48 h (RIG-I: p \< 0.0001; MDA5: p \< 0.0001; MAVS: p = 0.0008) post-infection. We also infected THP-1 cells in which STING or cGAS expression was ablated. Consistent with previous results in murine cGAS^−/−^ and STING^−/−^ BMDM ([@bib92]), infection with H37Rv-mCherry resulted in significantly enhanced growth of MTb at 24 or 48 h post-infection relative to control cells ([Figure S2](#mmc1){ref-type="supplementary-material"}), which was comparable to that observed with disruption of individual RNA sensor proteins. Representative images of intracellular mycobacteria from the IFC/ImageStream analysis at the median fluorescence intensity level for each mutant cell line and its corresponding control cell line are shown in [Figure S3](#mmc1){ref-type="supplementary-material"}.

We next confirmed our findings in an independent classical colony-forming unit (CFU) analysis. Inhibition of RIG-I (p = 0.043), MDA5 (p = 0.045), MAVS (p = 0.041), and PKR (p = 0.045) each resulted in significant increase of MTb growth in comparison to THP-1 control cells by CFU analysis ([Figure 1](#fig1){ref-type="fig"}D). We note that there was no significant difference in numbers of bacteria between any of the cell lines with RNA sensor disruptions compared with their control cell lines at Day 0 after 4 h of MTb growth or at Day 2. Taken together, we conclude that the RLR and PKR RNA sensing pathways broadly inhibit MTb intracellular growth independently of the cGAS/STING DNA sensing pathway.

RIG-I, MDA5, and MAVS Activities Are Potentiated by MTb Infection and PKR Is Activated {#sec2.3}
--------------------------------------------------------------------------------------

We next sought to determine if MTb, in addition to inducing gene expression of cytoplasmic RNA sensors, amplified their activities. Previous studies of RLR activation have employed human embryonic kidney (HEK) 293T cells to overexpress RLRs and to test their response to specific activators ([@bib4], [@bib46], [@bib94], [@bib95]). To determine if 293T cells were an appropriate model system to evaluate MTb-stimulated RLR activities, we first established that MTb could infect these cells. We note that although MTb can proliferate in renal cells ([@bib23]), 293T cells are not a typical cell line in which to study MTb infection. As shown in [Figure 2](#fig2){ref-type="fig"}A, H37Rv-mCherry MTb infection and growth in 293T cells were detectable by flow cytometry when cells were infected with bacteria at a ratio of 1:1 or 1:10 after 24 ([Figure 2](#fig2){ref-type="fig"}A, top row) or 48 h ([Figure 2](#fig2){ref-type="fig"}A, bottom row).Figure 2MTb Enhances RLR and PKR Activities(A) 293T cells were left uninfected or infected with MTb strain H37Rv-mCherry (1:1 or 1:10 cell:bacilli) for 24 h (top row) or 48 h (bottom row) and analyzed by flow cytometry. Gated area and numerical values show the percentage of the cells infected with bacilli. Dot plots are representative of three independent experiments.(B) ImageStream quantitative IFC analysis of 293T cells infected with H37Rv-mCherry at 1:10 cell:bacilli for 24 h (left) or 48 h (right) comparing WT 293T control cells with cells in which RIG-I, MDA5, or MAVS expression was disrupted by gene editing as described in [Methods](#sec4){ref-type="sec"}. A control 293T cell line that was parental to the specific gene-edited clone was used as described previously ([@bib2], [@bib98], [@bib104]). Data were analyzed using the Mann-Whitney Test and are representative of three independent experiments acquiring ∼5,000 cells per sample each time. Please see [Figure S1](#mmc1){ref-type="supplementary-material"}C for Western blot analysis showing ablation of protein expression of RIG-I, MDA5, and MAVS, in 293T cells where expression of these genes have been disrupted.(C) IFN-β mRNA expression (left panel) and IFITM3 mRNA expression (right panel) in 293T cells transfected with human RIG-I, MDA5, or MAVS expression vector or empty vector control in uninfected cells or cells infected with MTb (1:10 cell:bacilli) for 24 h. Data were analyzed using the unpaired Student\'s t-test and are presented as mean ± SEM of three independent experiments.(D) Left: Western blot analysis of total PKR and eIF2α, and phosphorylated PKR and eIF2α, and tubulin from control and MTb (H37Rv)-infected (24 h) THP-1 cells. Right: densitometric analysis of the data is presented in histogram format. Please see [Figure S4](#mmc1){ref-type="supplementary-material"} for Western blot analysis of RIG-I, MDA5, and MAVS protein levels in THP-1 cells after MTb (H37Rv) infection.

Given the infectability of 293T cells by MTb, we next examined whether endogenous RIG-I, MDA5, or MAVS within 293T cells played a role in restriction of H37Rv MTb growth in these cells. Infection of CRISPR/Cas9 gene-edited 293T cells in which RIG-I, MDA5, or MAVS expression was ablated ([Figure S1](#mmc1){ref-type="supplementary-material"}C) resulted in significant increase of intracellular growth of MTb relative to control 293T cells evaluated by IFC ([Figure 2](#fig2){ref-type="fig"}B). Thus, MTb infection of 293T cells is restricted by RLR proteins, which mirrored our findings of their role in the monocytic THP-1 cells ([Figure 1](#fig1){ref-type="fig"}C).

We thus next overexpressed RIG-I, MDA5, or MAVS in 293T cells and infected the cells with MTb H37Rv at a ratio of 1:10 ([Figure 2](#fig2){ref-type="fig"}C). Twenty-four hours later we measured IFN-β ([Figure 2](#fig2){ref-type="fig"}C, left panel) and IFITM3 ([Figure 2](#fig2){ref-type="fig"}C, right panel) mRNA levels. Expression of both IFN-β and IFITM3 was significantly enhanced by MTb infection in comparison to overexpression of each RNA sensor in the absence of MTb infection ([Figure 2](#fig2){ref-type="fig"}C). Thus, MTb amplifies the activity of RIG-I and MDA5 and their signaling adaptor protein MAVS, resulting in increased levels of IFN-β and IFITM3 mRNA.

Activation of PKR can be measured by detection of its auto-phosphorylated form ([@bib16], [@bib34], [@bib88]) and by phosphorylation of its substrate eIF2α ([@bib15], [@bib24], [@bib33], [@bib43], [@bib63]). To test if MTb activated PKR, we infected THP-1 cells with H37Rv MTb for 24 h, prepared cellular extracts, and performed a Western blot analysis. We observed higher levels of total PKR protein and its phosphorylated active form and higher levels of phosphorylated eIF2α protein after MTb infection ([Figure 2](#fig2){ref-type="fig"}D). Thus, MTb infection enhances PKR activity in THP-1 cells as evidenced by the increased phosphorylation of eIF2α. We note that the MTb-induced protein expression of RIG-I, MDA5, and MAVS ([Figure S4](#mmc1){ref-type="supplementary-material"}) was also directly correlated with their RNA expression shown in [Figure 1](#fig1){ref-type="fig"}A.

NTZ Enhances MTb-Induced Gene Expression and Activity {#sec2.4}
-----------------------------------------------------

Our recent studies have shown that the FDA-approved small molecule drug, NTZ, enhances RLR and PKR activity in human cells ([@bib46]). Given our results above, we tested its effect on MTb-driven RIG-I, MDA5, MAVS, and PKR gene expression in THP-1 cells. THP-1 cells were exposed to vehicle (DMSO) or 10 μM NTZ for 4 h and then infected with MTb. As shown in [Figure 3](#fig3){ref-type="fig"}A, NTZ augmented MTb induction of RIG-I (p = 0.04), MDA5 (p = 0.03), PKR (p = 0.01), and MAVS (p = 0.06) mRNA levels.Figure 3NTZ Enhances MTb-induced RLR and PKR Gene Expression and MTb-Activated RLR Activity(A) mRNA levels of RIG-I, MDA5, MAVS, and PKR from THP-1 cells exposed to vehicle or 10 μM NTZ for 4 h and then infected with MTb (1:10 cell:bacilli) for 24 h, as indicated. Data were analyzed using the unpaired Student\'s t-test and are presented as mean ± SEM of three independent experiments.(B) mRNA levels of IFN-β (top panel) or IFITM3 (bottom panel) from 293T cells transfected with empty vector or expression vectors for RIG-I, MDA5, or MAVS and treated with vehicle or with 10 μM NTZ for 4 h followed by 24 h of MTb infection as indicated. Data were analyzed using the unpaired Student\'s t-test and are presented as mean ± SEM of three independent experiments. Please see [Figure S5](#mmc1){ref-type="supplementary-material"} for examination of NTZ\'s effect on PKR phosphorylation.

To test whether NTZ amplified MTb-driven RLR activities in 293T cells overexpressing RIG-I, MDA5, or MAVS, we next examined the impact of treatment of the cells with 10 μM NTZ for 4 h prior to MTb infection. As shown in [Figure 3](#fig3){ref-type="fig"}B, NTZ pretreatment significantly increased MTb-induced IFN-β and IFITM3 gene expression in cells overexpressing RIG-I (p = 0.02; p = 0.02), MDA5 (p = 0.01, p = 0.01), or MAVS (p = 0.01; p = 0.004), respectively. Previous studies ([@bib8], [@bib30]) have suggested that phosphorylation of PKR is increased by NTZ treatment. We thus also evaluated levels of PKR or phosphorylated PKR in cellular extracts from THP-1 cells stimulated with 10 μM NTZ or vehicle for 4 h and then infected with MTb H37Rv for 24 h. We did not observe an NTZ-dependent increase in PKR phosphorylation in these cells ([Figure S4](#mmc1){ref-type="supplementary-material"}), consistent with a recent report ([@bib39]). Thus, NTZ broadly enhanced MTb-induced RIG-I, MDA5, and PKR mRNA expression and amplified MTb-dependent activation of the RLR proteins.

Inhibition of MTb Growth by NTZ {#sec2.5}
-------------------------------

NTZ has been reported to inhibit the growth of diverse strains of MTb cultured in cell-free media ([@bib17], [@bib26], [@bib25], [@bib36], [@bib64], [@bib71], [@bib82]). In one study using an H37Rv-luciferase reporter MTb strain, NTZ inhibited MTb replication in THP-1 cells when measured at 24, 48, and 72 h after infection ([@bib54]). By contrast, in another study utilizing a whole blood assay (WBA) ([@bib89]) of human donor cells and H37Rv, a significant inhibitory effect of NTZ was not appreciated, which the authors suggested was due to low bioavailability of the highly protein-bound drug ([@bib36]). We note that another WBA-based study did not show an inhibitory effect upon MTb of orally administered clofazimine ([@bib45]), which, as is the case with NTZ, is also highly protein-bound ([@bib78]), even though clofazimine is now effectively used as a therapy for drug-resistant TB that is refractory to second-line agents ([@bib44]).

To test NTZ\'s effect on MTb growth, we first treated THP-1 cells with 5 or 10 μM NTZ (or vehicle) 4 h before or 4 h after infection with H37Rv-mCherry at cell to bacteria ratios of 1:1 and 1:10 and evaluated MTb growth 24 or 48 h post-infection by FACS. NTZ-dependent inhibition of MTb growth was evident when NTZ (5 or 10 μM) was added 4 h prior to MTb infection but not when it was added 4 h after infection irrespective of cell to bacteria ratio ([Figure 4](#fig4){ref-type="fig"}A).Figure 4NTZ and NTZ derivatives Inhibit MTb Infection in Human Monocytic Cells and PBMC(A) THP-1 cells were treated with 5 or 10 μM of NTZ 4 h before or 4 h after infection with MTb strain H37Rv-mCherry (1:1 cell:bacilli, top row; or 1:10 cell:bacilli, bottom row) for 20 h and analyzed by flow cytometry. Gated area and numerical values show the percentage of the cells infected with bacilli. Dot plots are representative of three independent experiments.(B) Quantitative IFC analysis of THP-1 cells treated with 5 or 10 μM of NTZ 4 h before or 4 h after infection with MTb strain H37Rv-mCherry (1:10 cell:bacilli) for 24 or 48 h as indicated. Dot plot graphs show the pixel intensity of intracellular mCherry in the infected cells after ImageStream acquisition. Data were analyzed using the Mann-Whitney Test and are representative of three independent experiments, acquiring ∼5,000 cells per sample each time.(C) NTZ, TIZ, and RM5061 inhibit MTb in human PBMC. Left panel: CFU assay of normal PBMC at 0, 1, 2, 3, and 4 days after treatment with 10 μM of NTZ, TIZ, RM5061, or treated with vehicle as a control for 4 h followed by infection with H37Rv (1:10 cell: bacilli). Data were analyzed using the unpaired Student\'s t-test and are presented as mean ± SEM of four independent experiments in triplicate. Table shows complete statistics. Right panel: cell viability in response to increasing concentrations of NTZ and TIZ. Normal donor PBMC were treated with 10 or 20 μM of NTZ, TIZ, or RM5061, or treated with vehicle as a control for 24 h. Cells were harvested, stained with Annexin V-FITC, and subjected to flow cytometry analysis. Data were analyzed using the unpaired Student\'s t-test and are presented as mean ± SEM of four independent experiments.

To further quantify this effect, we evaluated NTZ\'s impact by IFC and the ImageStream platform. As shown in [Figure 4](#fig4){ref-type="fig"}B, when 5 or 10 μM NTZ was added 4 h prior to H37Rv-mCherry infection of THP-1 cells, there was a highly significant inhibitory effect on MTb growth at both 24 (p = 0.008, p \< 0.0001) and 48 h (p \< 0.0001, p \< 0.0001). By contrast, when 5 or 10 μM NTZ was added 4 h after infection, no MTb inhibition was observed at 24 (p = 0.28, p = 0.63) or 48 h (p = 0.46, p = 0.11). Our data indicate that detection of NTZ\'s host-dependent effects is maximized by pretreatment of cells with NTZ prior to infection.

To confirm our findings showing NTZ inhibition of MTb growth by FACS and IFC, we next performed a third independent analysis of NTZ\'s impact on MTb growth by quantifying CFUs using the H37Rv MTb strain and primary human donor peripheral blood mononuclear cells (PBMC) from four individuals. For these experiments, we employed NTZ, its active circulating metabolite, tizoxanide (TIZ) ([@bib77]), and a recently developed water-soluble prodrug derivative of TIZ, RM5061 (also known as aminoxanide or L-tert-leucyl thiazolide), which has a seven-fold higher blood concentration relative to NTZ in rats, with absolute bioavailability increasing from 3% to 20% ([@bib84]) and which is in pre-clinical development for phase I human trials ([@bib28]). Pretreatment of donor PBMC with 10 μM NTZ, TIZ, or RM5061 for 4 h prior to MTb infection resulted in a highly significant reduction of MTb growth in the thiazolide drug-treated cultures after two (NTZ: p = 0.0112; TIZ: p \< 0.0001; RM5061: p = 0.0457), three (NTZ: p = 0.001; TIZ: p \< 0.0001; RM5061: p = 0.0087), and four (NTZ: p = 0.0001; TIZ: p \< 0.0001; RM5061: p = 0.0036) days of MTb growth ([Figure 4](#fig4){ref-type="fig"}C, left).

In addition, there was no evidence of drug cytotoxicity based on the percentage of viable PBMCs detected by Annexin V-FITC staining following treatment with 10 or 20 μM NTZ, TIZ, or RM5061 relative to control cells for 24 h ([Figure 4](#fig4){ref-type="fig"}C, right). We note that 10 μM NTZ or TIZ is well below peak plasma levels of ∼39 μM TIZ observed after an oral dose of 500 mg of NTZ ([@bib86]), which is a typical twice-a-day oral dosage of the drug ([@bib85]). Thus, taken together, these results demonstrate that NTZ, TIZ, or the new NTZ derivative RM5061 inhibits intracellular MTb growth in human cells measured using three distinct quantitative *in vitro* analyses, including by CFU in primary human PBMC.

Discussion {#sec3}
==========

Here we have shown that that RIG-I, MDA5, MAVS, and PKR each play a significant functional role in the cell-intrinsic control of intracellular MTb growth in human cells. Furthermore, we have shown that the broad expression and activity of the major RLR signaling proteins RIG-I, MDA5, and MAVS and the RLR-independent signaling protein PKR are increased by MTb infection of human cells. We have also demonstrated that the FDA-approved oral drug NTZ, which amplifies RLR, PKR, and interferon activities ([@bib46]), significantly inhibits MTb growth in human cells.

Two principal components of host cytoplasmic RNA surveillance, the RLR and PKR pathways, were initially characterized as part of the innate immune response to cytoplasmic viral RNA ([@bib6], [@bib15], [@bib52], [@bib57], [@bib59], [@bib63], [@bib80], [@bib97], [@bib100], [@bib99]). However, bacterial RNA can also interact with PKR ([@bib12], [@bib13], [@bib42]) and RLRs ([@bib1], [@bib18], [@bib60], [@bib73]). Independent findings using a murine system demonstrated a role for RIG-I and MAVS in MTb-induced IFN-β expression in macrophages ([@bib18]). Furthermore, this group showed that MTb RNA-containing extracellular vesicles (EVs) isolated from MTb-infected cells promoted IFN-β expression and mycobacterial killing in recipient macrophages in an RIG-I- and MAVS-dependent fashion ([@bib19]). These studies did not, however, examine the role of these sensors in inhibition of intracellular MTb growth within the initially infected host cell, nor did they reveal a role for MDA5 or PKR in these processes, nor the role of MTb in the induction of their transcription or activation.

By contrast, our data here show that two major proximal sensors in the RLR/MAVS cytosolic RNA surveillance pathway, RIG-I and MDA5, and the RLR-independent PKR pathway are induced by MTb infection and play non-redundant roles in the cell-intrinsic response to inhibit MTb growth. We note that RIG-I and MDA5 recognize their RNA ligands via distinct mechanisms prior to their interaction with MAVS ([@bib35], [@bib76], [@bib87]). RIG-I binds to the ends of short dsRNAs, exhibiting a preference for blunt ends and 5′ triphosphates ([@bib40], [@bib49], [@bib72]), and then assembles into tetrameric structures ([@bib69], [@bib68]). By contrast, MDA5 binds to internal sequences, rather than the ends, of long dsRNAs, assembling cooperatively into filaments along the RNA ([@bib11], [@bib67], [@bib69], [@bib94]). The multimerization of RIG-I or MDA5, in turn, promotes the aggregation of MAVS at the mitochondrial membrane, leading to downstream signaling ([@bib11], [@bib41], [@bib47], [@bib67], [@bib68], [@bib81], [@bib95]). Thus, our data indicate that MTb RNAs expressed during active MTb infection can trigger both the RIG-I and MDA5 arms of the RLR pathway.

The mechanism and function of PKR is distinct from the RLR/MAVS pathway ([@bib15], [@bib43], [@bib63]). Instead of triggering activation of MAVS, leading to activation of the transcription factor IRF3 ([@bib35], [@bib76], [@bib87]), PKR is involved in shutdown of protein synthesis via phosphorylation of eIF2α and can directly or indirectly activate kinase pathways, including MAP kinases and those leading to NF-κB activation resulting in innate immune gene expression ([@bib15], [@bib24], [@bib33], [@bib35], [@bib43], [@bib63]). Furthermore, PKR can be activated by a number of stimuli apart from RNA, such as TLR engagement, oxidative stress, growth factors, and cytokines ([@bib15], [@bib24], [@bib33], [@bib63]). Early studies showed that the PKR inhibitor 2-aminopurine inhibited lipopolysaccharide-driven TNF gene expression (Goldfeld and Maniatis, 1989). *Mycobacterium bovis* bacillus Calmette-Guérin (BCG) was later found to induce transcription of TNF, interleukin 6 (IL-6), and IL-10, as well as promote phosphorylation of PKR in a 2-aminopurine-sensitive fashion ([@bib20]). As an RNA sensor, PKR responds to multiple synthetic and viral DNAs, undergoing dimerization induced by dsRNA interaction as well as other stimuli ([@bib15], [@bib43]).

Although PKR\'s role in IFN-β gene expression has been characterized by a number of studies ([@bib24], [@bib33], [@bib63]), PKR\'s role in TB has not been clarified. Although a previous study reported that PKR^−/-^ mice had a reduced MTb burden ([@bib96]); the same group later attributed that finding to an error in mouse strain background and not to PKR directly ([@bib62]). Here, we have shown that MTb infection causes an increase in PKR mRNA and protein levels and in phosphorylation of its substrate eIF2α in human cells. Furthermore, we have shown that PKR deficiency results in significantly enhanced intracellular MTb growth by both IFC and CFU analyses. Taken together, our studies thus demonstrate that proteins of both the RLR/MAVS and PKR cytoplasmic RNA sensor pathways are critical components of host restriction of intracellular MTb growth in human cells.

Here, we have also shown that NTZ broadly enhances MTb-driven RLR/MAVS activities, resulting in increased IFITM3 and IFN-β gene expression, and that it increases gene expression of RIG-I, MDA5, and PKR, extending the immunomodulatory effect of NTZ to antimycobacterial host gene activity. The details of how MTb infection regulates expression of the host RNA sensing pathway, the role of type I IFNs, and how NTZ amplifies these effects in TB pathogenesis remain to be explored further. We also observed that, similar to MTb infection, MTb lysate increased mRNA expression of the ISGs RIG-I, MDA5, PKR, and IFITM3. MTb glycolipoproteins, lipoproteins, and glycolipids present in the lysate are ligands for TLR4 and TLR2, which can in turn trigger activation of IRF3 and, more broadly, type I IFNs ([@bib31], [@bib70]); thus, the TLR and IRF/IFN pathways may play a complementary role in this context. Indeed, we note that there is evidence that IRF3 can regulate the gene promoters of both RIG-I and MDA5 ([@bib38], [@bib101]) and that interferon-stimulated gene factor 3 (ISGF-3) can regulate the PKR gene promoter ([@bib90]). Furthermore, given that NTZ can promote IRF3-driven IFN-β mRNA expression in addition to its ability to broadly amplify RLR activity ([@bib46]), it is intriguing to speculate that MTb and NTZ directly enhance gene expression of sensor molecules via their effects on upstream transcriptional activators.

Finally, our demonstration of the key role of cytoplasmic RNA sensor proteins in the cell-intrinsic control of MTb growth and the ability of NTZ to amplify their effects suggest them as attractive targets for chemical regulation to inhibit MTb. Current antimycobacterial treatment regimens are long and complex, complicated by evolving drug resistance and a large burden of disease caused by multi-drug resistant TB ([@bib14]). NTZ has a long track record of safety, including in HIV co-infected individuals ([@bib3]). It is of low cost and available as an oral agent, including as a pediatric syrup formulation ([@bib77]), making it an easily scalable treatment for adults and children. Our demonstration here showing highly significant NTZ inhibition of intracellular MTb growth in THP-1 cells and in donor PMBCs thus also provides support for the repurposing of NTZ, or newer NTZ derivatives, as a host-directed TB therapy to complement canonical TB treatment regimens.

Limitations of the Study {#sec3.1}
------------------------

We have not yet established the role of type I IFNs in MTb induction of RNA sensor transcription or the role of type I IFNs in NTZ\'s amplification of MTb-driven RNA sensor activities. These studies, as well as the investigation and identification of NTZ\'s upstream target(s) are outside the scope of this article and will be the subject of future research.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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Document S1. Transparent Methods and Figures S1--S5
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